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Novel roles of the endocannabinoid system in modulating synaptic plasticity 
 
Chairperson:  Michael P. Kavanaugh, Ph.D.  
 
  Learning and memory formation are invaluable processes in human life; however, the 
cellular mechanisms that control these phenomena are largely unknown. Synaptic 
plasticity, which is the ability of the synapse between two neurons to change in strength 
based on activity, is believed to be a key process in the formation of memories and 
learning. Endocannabinoids (eCB) have recently emerged as important modulators of 
synaptic plasticity but their precise roles and mechanisms are not well understood and 
many contradictions exist in the current literature. We have investigated the roles of eCBs 
and their primary receptor, the CB1 receptor, in the central nervous system using 
electrophysiological recordings in rodent hippocampus.  We find that a moderate 
frequency 10 Hz stimulation protocol produces long-term potentiation (LTP) that is 
modulated by eCBs in both mice and rats; but surprisingly, the roles played by eCBs 
differ greatly between species. In rats, 10 Hz LTP requires CB1 receptor activation, as it 
is completely abolished by the CB1 antagonists AM251 and SR141716. Unlike theta 
burst stimulation (TBS) induced LTP, 10 Hz LTP does not require NMDA receptor 
activation. However, it is prevented when both NMDA and group1 mGluR receptors are 
blocked. The 10 Hz LTP is also independent of GABAergic synaptic inhibition, 
suggesting it is a novel form of excitatory synaptic plasticity mediated by the eCB system 
in hippocampus. In mice, we find that CB1 has an inhibitory effect on 10 Hz induced 
LTP. When the receptor is genetically removed in CB1 (-/-) mice or pharmacologically 
blocked wild type mice, 10 Hz LTP is greatly facilitated. Similar to TBS LTP, 10 Hz 
LTP in mice is NMDA receptor mediated. Also, the ability to achieve successful long-
term depression (LTD) is decreased in CB1 (-/-) mice; yet, the magnitude of successful 
LTD is not changed. Together, this data supports a role for the CB1 receptor in inhibiting 
the induction of LTP with moderate stimulation protocols in mice, while in rats CB1 
activation is required for 10 Hz LTP. Overall, our data supports that eCBs are crucial 
modulators of synaptic plasticity, although the roles they play may differ among species.  
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
 
Humans have been captivated by the properties of Cannabis sativa, both for 
recreational and medicinal purposes, for thousands of years. The world’s oldest known 
pharmacopoeia, the Pen-ts’ao Ching from China, describes its use as far back as 2727 
B.C. Since then, countless cultures and societies have reported on its many uses and 
effects, which have included some interesting consequences on memory and learning 
(Murray et al., 2007). Despite this tremendous interest, it is only within the last 50 years 
that the mechanisms by which Cannabis acts on the mind and body have begun to be 
identified.  
 
The endocannabinoid system is discovered 
The first major breakthrough in the cannabinoid field came in 1964 when Raphael 
Mecholulam’s lab identified !9-tetrahydrocannabinol (THC) as the major psychoactive 
component of cannabis (Gaoni and Mechoulam, 1964; Gaoni and Mechoulam, 1971). 
This discovery fueled an intense search for a receptor, which continued for over 20 years 
until the cannabinoid 1 (CB1) receptor was identified in 1988 (Devane et al., 1988) and 
then cloned in 1990 (Matsuda et al., 1990).  A second cannabinoid receptor, CB2, was 
subsequently discovered and cloned in 1993 (Munro et al., 1993); however, it is 
predominantly located in cells of the immune system and not the central nervous system 
(Axelrod and Felder, 1998; Pertwee, 1997). Currently, there is great interest in the 
cloning of a third cannabinoid receptor, and many pieces of evidence point to its 
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existence in the brain (Begg et al., 2005; Lauckner et al., 2008; Mackie and Stella, 2006; 
Ryberg et al., 2007). 
The second major breakthrough for cannabinoid research occurred when 
endocannabinoids (eCBs), which are endogenous ligands for the cannabinoid receptors, 
were discovered. Currently there are two well-characterized eCBs although many other 
possible ligands have been identified.  The first eCB to be discovered was N-
arachidonoylethanolamide, named anandamide (AEA) for the Sanskrit word anada, 
which means bliss (Devane et al., 1992). Several years later a second eCB, 2-
arachidonoylyglycerol (2-AG), was also isolated (Mechoulam et al., 1995; Sugiura et al., 
1995). These eCBs share some overlap in distribution the CNS and for the most part 2-
AG is found in much higher concentrations (Stella et al., 1997; Sugiura et al., 1995). 
The endocannabinoids have several properties that make them unique as 
neurotransmitters. Most notably, they are not stored in vesicles and thus do not require 
vesicular fusion for release. Instead, they are membrane bound lipid precursors that are 
enzymatically activated and released directly into the synaptic cleft by cleavage from the 
membrane. Endocannabinoid release is a calcium dependent process and occurs in 
response to cell depolarization (Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2001) or 
activation of group1 metabatropic glutamate receptors (mGluRs) (Ohno-Shosaku et al., 
2002a; Varma et al., 2001). Although these processes occur independently, both cause an 
increase in intracellular calcium concentration, which is key for endocannabinoid 
synthesis (Cadas et al., 1996; Di Marzo et al., 1994; Stella and Piomelli, 2001; Stella et 
al., 1997). There is also evidence that dopaminergic and muscarinic acetylcholine 
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receptor activation can lead to endocannabinoid production, but these pathways are not as 
well characterized (Giuffrida et al., 1999; Kim et al., 2002). 
 
Endocannabinoid synthesis & degradation 
Anandamide and 2-AG are independently synthesized through multi-step 
processes. Anandamide synthesis begins when N-acytltransferase joins the precursor lipid 
phosphatidylethanolamine (PE) with an arachidonate group to create N-arachidonyl-PE. 
Phospholipase D (PLD) then catalyzes the hydrolysis of N-arachidonyl-PE to create 
anandamide. Increases in intracellular calcium initiate both the formation of N-
arachidonyl-PE and its conversion to anandamide (Freund et al., 2003). 2-AG synthesis 
follows two possible routes both starting with the lipid precursor phosphatidylinositol 
(PI). In one route, PI is acted upon by phosopholipase C (PLC) to create 1,2-
diacylgelycerol (1,2-DAG), which is then converted to 2-AG via diacylglycerol lipase.  
In the other route, PI is acted upon by phospholipase 1A (PL1A) to create 2-
arachindonlyl-lysophospholipid, which is converted to 2-AG through Lyso-PLC activity. 
Increases in intracellular calcium concentration have also been found to stimulate 2-AG 
release, likely through the above pathways (Stella and Piomelli, 2001; Stella et al., 1997).  
Endocannabinoid synthesis is also unique in that it occurs postsynaptically. Such 
neurotransmitters are known as retrograde messengers, meaning they are released 
postsynaptically and then traverse the synapse “backwards” to bind presynaptic targets. 
This interesting mode of action was first described when a unique form of short term 
plasticity, termed depolarization-induced suppression of inhibition (DSI), was discovered 
in cerebellum (Llano et al., 1991) and hippocampus (Pitler and Alger, 1992). DSI 
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required depolarization of a postsynaptic neuron to inhibit neurotransmitter released by 
presynaptic inputs.  At the time of these discoveries, it was not known which retrograde 
neurotransmitters were responsible for DSI. This work showed that the synapse could 
transmit messages in both directions and these actions may have important roles in 
modulating synaptic strength. Later, once the CB1 receptor had been better characterized 
and endocannabinoids were discovered, it was revealed that the endocannabinoid 
neurotransmitter system mediated DSI (Diana et al., 2002; Kreitzer and Regehr, 2001a; 
Ohno-Shosaku et al., 2001; Varma et al., 2001; Wilson and Nicoll, 2001).  
Aside from elucidating a retrograde neurotransmission system, DSI also describes 
an important form of plasticity mediated by eCBs; however, before the roles of 
endocannabinoids in synaptic plasticity can be discussed, the termination of eCB 
signaling must be considered.  Once released, AEA and 2-AG are taken back into neuron 
terminals through a carrier mediated process. Although an eCB transporter is yet to be 
cloned, there are several pieces of evidence supporting its existence. AEA and 2-AG 
uptake is saturable and these two ligands can inhibit one another’s uptake, suggesting a 
shared transporter. Uptake is also temperature dependent, has a faster clearance rate than 
diffusion, and exhibits substrate selectivity (Beltramo et al., 1997; Di Marzo et al., 1994; 
Hillard et al., 1997). In addition, a transporter inhibitor, AM404, has been discovered. 
AM404 is an anandamide analog that does not activate receptors but effectively blocks 
both AEA and 2-AG clearance (Beltramo and Piomelli, 2000; Bisogno et al., 2001). The 
endocannabinoid transporter seems to be present on both neurons and glia. Its operation 
does not require energy expenditure from the cell, which likely makes it a process of 
facilitated diffusion (Beltramo et al., 1997; Hillard et al., 1997). 
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Once eCBs are successfully transported into neurons they are rapidly hydrolyzed. 
Anandamide is broken down into arachadonic acid and ethanolamine by the enzyme fatty 
acid amide hydrolase (FAAH) (Cravatt et al., 2001; Cravatt et al., 1996). FAAH is found 
throughout the brain and its distribution accurately overlays known regions of 
endocannabinoid signaling (Desarnaud et al., 1995; Hillard et al., 1995; Thomas et al., 
1997). 2-AG is mainly hydrolyzed by the enzyme monoglyceride lipase (MGL) and 
converted into glycerol and a fatty acid (Karlsson et al., 1997). MGL expression has also 
been shown throughout the brain, with the highest levels corresponding to areas of CB1 
receptor expression and 2-AG release (Dinh et al., 2002).  
 
The CB1 receptor 
Just as it is important to understand how endocannabinoids are synthesized and 
degraded, it is equally important to understand the actions of their receptors. I will focus 
on CB1 and it’s effects on synaptic plasticity as it is the predominant receptor in the 
brain. The cannabinoid receptors are G-protein coupled and act through Gi/o protein 
signaling. Upon activation, CB1 inhibits adenylyl cyclase activity, which decreases 
cytosolic cyclic AMP concentrations and activates mitogen activated protein kinases 
(Adams and Sweatt, 2002; Bouaboula et al., 1995).  Initiation of these second messenger 
systems can affect gene regulation, which is important for the maintenance of long-term 
synaptic changes.  Also, CB1 activated Gi/o proteins inhibit L, N, and P/Q type voltage-
gated calcium channels and activate inwardly rectifying potassium channels. These 
channel effects likely occur through direct interactions with the ß" subunit of the G-
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protein (Howlett et al., 2002; Pertwee, 1997). Together these actions inhibit presynaptic 
neurotransmitter release in the targeted cell.  
CB1 is one of the most abundantly expressed GPCR receptors in the brain and has 
been found in many regions; with the highest levels of expression in hippocampus, 
cerebellum, cortex, amygdala, and basal ganglia (Freund et al., 2003; Herkenham et al., 
1990; Howlett et al., 2002; Mackie, 2005). It is imperative to recognize that regions of 
high expression are also areas of key importance to learning and memory function. 
Immunohistochemical analysis shows that CB1 receptors are strongly expressed on 
synaptic terminals of cholecystokinin-containing (CCK) inhibitory interneurons in 
hippocampal region CA1 (Hajos et al., 2000; Katona et al., 2001; Katona et al., 2000; 
Katona et al., 1999; Marsicano et al., 2002; Tsou et al., 1999). When activated they 
inhibit GABA release, and most of CB1’s actions in hippocampus are attributed to this 
mechanism (Hoffman, 2000; Kreitzer and Regehr, 2001b; Levenes et al., 1998; Ohno-
Shosaku et al., 2001; Wilson and Nicoll, 2001). 
Yet, despite the view that CB1 only acts on inhibitory interneurons in 
hippocampus to regulate GABA release, there is accumulating evidence supporting a role 
for CB1 in the modulation of excitatory signaling. Several groups have demonstrated that 
application of the CB1 receptor agonist WIN55,212-2 depresses presynaptic excitatory 
signaling, as seen by a decrease in EPSP amplitude and increased paired pulse ratio (Al-
Hayani and Davies, 2000; Hajos and Freund, 2002; Hajos et al., 2001; Hoffman et al., 
2005; Misner and Sullivan, 1999; Takahashi and Castillo, 2006). These effects do not 
occur in CB1(-/-) genetic knockout animals and they are reversed by application of CB1 
antagonists (Hoffman et al., 2005; Misner and Sullivan, 1999; Takahashi and Castillo, 
 7 
2006). It should also be noted that WIN55,212-2  depresses IPSC amplitudes, which 
supports CB1’s presence on GABAergic neurons (Hajos and Freund, 2002; Hoffman and 
Lupica, 2000).  
Aside from the WIN55,212-2 evidence, several other observations suggest that 
CB1 can affect glutamatergic signaling. CB1 mRNA has been found in CA3 pyramidal 
cells, whose axons make up the Schaffer collaterals that synapse on CA1 pyramidal cell 
dendrites in the stratum radiatum (Marsicano et al., 2003). The enzymatic machinery 
responsible for the synthesis of eCBs has also been found in glutamatergic inputs (Nyilas 
et al., 2008), and depolarization induced suppression of excitation (DSE), which is 
similar to DSI except that it inhibits presynaptic release from glutamatergic terminals, has 
been found in regions including hippocampus (Hajos et al., 2001; Kreitzer and Regehr, 
2001b; Ohno-Shosaku et al., 2002b; Straiker and Mackie, 2005). Although there is not 
clear immunohistochemical data supporting CB1’s existence on glutamatergic terminals 
in hippocampus physiological data does support this possibility. 
 
Endocannabinoids and synaptic plasticity 
Cannabinoid receptors presence on both inhibitory and excitatory neurons has 
important implications for the control of synaptic strength and plasticity. Synaptic 
plasticity is the ability of a synapse to undergo changes in strength based on prior 
activity, and it can be either short-term, lasting on the order of seconds to minutes, or 
long-term, lasting for hours or even days in some in vivo models. The ability of a synapse 
to change strength is believed to underlie the crucial processes of learning and memory 
formation. 
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There are many types of synaptic plasticity, which vary depending on the types of 
neurons involved, the duration of the change, the direction of change, and the brain 
region involved. The most widely studied form of synaptic plasticity is long-term 
potentiation (LTP), which was discovered in 1973 (Bliss and Lomo, 1973). In this initial 
report, which used recordings from the hippocampus of anesthetized rabbits, it was found 
that repetitive stimulation paradigms caused an increase in synaptic response that could 
last from 30 minutes up to 10 hours. This new phenomena exhibited pathway specificity, 
saturation, and was associative. These have since all been further described as traits of 
LTP. Overall, LTP can be defined as a sustained increase in synaptic response following 
the administration of specific stimulation paradigms (Malenka and Bear, 2004).  
Just as it is important to strengthen synaptic connections it is equally necessary to 
reverse potentiation and depress a synaptic connection. Long-term depression (LTD) is 
described as the ability of a synapse to show a sustained decrease in response following 
specific stimulation paradigms. The discovery of LTD came in two parts. First, it was 
found that LTP could be reversed, or depotentiated, bringing synaptic transmission back 
to baseline levels following a potentiation (Barrionuevo et al., 1980; Fujii et al., 1991; 
Staubli and Lynch, 1990). Secondly, it was discovered that basal synaptic responses 
could be depressed with low-frequency stimulus paradigms (Dudek and Bear, 1992). LTP 
and LTD both can occur in many regions of the brain between many different types of 
synapses. Some of the major regions used to reliably study plasticity, such as 
hippocampus, cortex, and cerebellum, are also known to be very important for learning 
and memory formation. 
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Aside from the long-term synaptic plasticities, there are also various forms of 
short-term plasticity, which completely reverse and last on the order of seconds to 
minutes. There are two forms of short-term plasticity that are of great importance to the 
endocannabinoid field. These are depolarization induced suppression of inhibition (DSI) 
and depolarization-induced suppression of excitation (DSE). In both DSI and DSE the 
release of neurotransmitter, either GABA (DSI) or glutamate (DSE), is temporarily 
inhibited following a brief postsynaptic depolarization. DSI was independently 
discovered in cerebellum (Llano et al., 1991) and hippocampus (Pitler and Alger, 1992), 
and as discussed previously, suggested the involvement of a retrograde messenger 
system, which was eventually shown to be the eCB system (Diana et al., 2002; Kreitzer 
and Regehr, 2001a; Ohno-Shosaku et al., 2001; Varma et al., 2001; Wilson and Nicoll, 
2001). When DSE was discovered in 2001, it was also reported to follow the same 
induction mechanisms as DSI, except that CB1 receptors on glutamatergic inputs were 
targeted instead of on GABAergic neurons (Kreitzer and Regehr, 2001a). 
In contrast to short term plasticity, eCBs’ also mediate a form of long-term 
depression known as inhibitory LTD (iLTD), which suppresses GABAergic signaling 
over extended time periods (Chevaleyre and Castillo, 2004).  In both DSI and iLTD, 
presynaptic GABA release is inhibited through CB1 receptor activation, causing a 
localized block of inhibitory signaling. Several papers have supported a role for CB1 in 
the facilitation of LTP, likely through this mechanism. Chevaleyre and Castillo (2004) 
showed that induction of iLTD facilitated greater LTP at the same recording site when 
compared to sites that did not undergo iLTD. Carlson et al (2002) also found that CB1 
activation during DSI allowed LTP induction with stimulus protocols that were normally 
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ineffective. These data fit with CB1’s currently accepted mechanism of action in 
hippocampus.  
In contrast, there are also several papers that describe a role of CB1 in the 
inhibition of excitatory LTP. The CB1 agonist WIN55,212-2 has been shown to block 
LTP (Misner and Sullivan, 1999) and 2-AG inhibits high-frequency stimulation (HFS) 
induced LTP (Stella et al., 1997). In the cortex, it has been observed that CB1 activation 
shifts the system in favor of LTD induction while CB1 block shifts the system towards 
LTP induction (Auclair et al., 2000). Also, Slanina et al (2005) found that CB1 inhibited 
LTP induced with moderate trains of stimulations, but did not affect LTP induced with 
robust HFS protocols, and Hoffman et al (2007) found that chronic THC exposure 
inhibits both HFS and theta burst (TBS) induced LTP, which was reversed by co-
administration of AM251. Interestingly this group also found that chronic CB1 block 
with the receptor antagonist AM251 enhanced TBS LTP but not HFS LTP. 
Several behavioral studies also support a role for CB1 in LTP inhibition. The CB1 
agonist HU-210 initially impaired water maze performance and LTP induction in-vivo 
(Hill et al., 2004), and similarly, spatial learning deficits and suppression of hippocampal 
pyramidal cell firing were observed in rats treated with the CB1 agonist HU-210 
(Robinson et al., 2007). 
 
Evidence for a novel cannabinoid receptor 
Although the CB1 receptor is thought to be responsible for most endocannabinoid 
actions in the brain, there is strong evidence for a third cannabinoid receptor that may 
also play important roles in neuronal signaling and synaptic plasticity (Begg et al., 2005; 
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Lauckner et al., 2008; Mackie and Stella, 2006; Ryberg et al., 2007). Hajos et al (2001) 
found that the CB1 agonist WIN55,212-2 inhibited EPSCs in both wild type and CB1 (-/-
) mice, suggesting a novel eCB receptor was present. It is important to note that they used 
adult mice of the Ledent strain (Ledent et al., 1999), which are backcrossed onto a CD1 
background, as discrepancies have arisen between the different strains of mice. In direct 
contrast, another group (Ohno-Shosaku et al., 2002b) found that WIN55,212-2 inhibited 
both EPSCs and IPSCs in wild type mice but not CB1(-/-) mice; however, they used 
juvenile CB1(-/-) mice of the Zimmer strain (Zimmer et al., 1999), which are backcrossed 
onto a C57Blk6 background. This group also found that both DSI and DSE could be 
induced in hippocampus, although stronger depolarizations were required to induce DSE. 
Also, both DSI and DSE were absent in CB1(-/-) mice, which argued against the 
involvement of a novel CB receptor in this strain and under these conditions. 
The confusion surrounding differences between species and strains of animals 
continued when yet another group found that wild type mice of the CD1 strain, the 
background for the Ledent knockouts, but not the C57Black6 strain, the background for 
the Zimmer knockouts, were sensitive to WIN55,212-2 (Hoffman et al., 2005). However, 
the most recent evidence suggests that WIN55,212-2 inhibition of fEPSPs is absent in 
CB1(-/-) mice of both strains, while inhibition of wild type fEPSPs remains intact 
(Takahashi and Castillo, 2006). 
Despite these inconsistencies, several other groups have collected data to support 
a novel receptor’s existence in CNS. Breivogel and colleagues (Breivogel et al., 2001) 
found that anandamide and WIN55,212-2 caused enhanced GTP"S binding in plasma 
membranes of brain tissue from CB1(-/-) mice, supporting the idea that another GPCR is 
 12 
activated by endocannabinoids. Also, in both wild type and CB1(-/-) mice activation of 
group 1 mGluR receptors has been reported to cause eCB release and mediate a short-
term depression of excitatory transmission, without affecting mGluR mediated long-term 
depression (Rouach and Nicoll, 2003).  Most recently an orphan GPCR known as GPR55 
has been classified as a novel cannabinoid receptor. Ryberg and colleagues showed, using 
cells expressing human GPR55, that anandamide and the cannabinoid agonist CP55940 
activated the receptor (Ryberg et al., 2007). More recently, an independent group has 
confirmed these results and found GPR55 to be activated by numerous cannabinoids 
(Lauckner et al., 2008). They have isolated GPR55 in the dorsal root ganglion of the 
spinal cord, and found that activation increases intracellular calcium while inhibiting M-
type potassium channels. Further investigation will show if GPR55 is also expressed 
throughout the brain and if this receptor could be the elusive CB3 others have described. 
 
Summary 
The goal of this thesis is to better understand how the endocannabinoid system 
modulates synaptic plasticity, in particular when a moderate frequency stimulation 
protocol is used to induce long-term potentiation (LTP). Two sets of experiments are 
presented in the following manuscripts. 
First, we show that brief trains of moderate frequency (10 Hz) stimulation results 
in an eCB-dependent LTP of excitatory synaptic transmission at rat Schaffer collateral-
CA1 pyramidal synapses. This LTP is distinct from traditional NMDA receptor mediated 
potentiation and requires activation of cannabinoid receptors. It represents a novel form 
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of excitatory synaptic plasticity mediated by the endocannabinoid system in 
hippocampus. 
Secondly, we aimed to further characterize the 10 Hz LTP using CB1 receptor 
knockout mice. However, this resulted in a second manuscript as we found the 10 Hz 
LTP to be quite different in mice. Here we found that CB1 receptor activation inhibited 
the 10 Hz potentiation, which was also NMDA receptor dependent, similar to traditional 
LTP. Together, this data supports a role for the CB1 receptor in inhibiting the induction 
of LTP with moderate frequency stimulation protocols. We also present data supporting 
the existence of a novel cannabinoid receptor, which may have a role in modulating 
synaptic plasticity. 
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Abstract 
  Modulation of synaptic transmission by endocannabinoids (eCBs) typically involves 
retrograde signaling resulting in presynaptic inhibition. Here we show that brief trains of 
moderate frequency (10 Hz) stimulation result in an eCB-dependent long-term 
potentiation of excitatory synaptic transmission at rat Schaffer collateral-CA1 pyramidal 
synapses. This potentiation is distinct from typical theta burst stimulus induced long-term 
potentiation (TBS-LTP) in that it is completely abolished by the CB1 receptor antagonists 
AM251 and SR141716, but not by the NMDA receptor antagonist AP5. This eCB-
dependent LTP is further distinguished from TBS/NMDAR-dependent LTP by the 
involvement of group I mGlu receptors and by marked age-dependence. The eCB-
dependent LTP was saturable and reached a maximum of 34 +/- 3.8% after 1-4 bouts of 
stimulation without occluding TBS/NMDAR-dependent LTP. This potentiation is 
independent of GABAergic synaptic inhibition, suggesting that it represents a novel form 
of excitatory synaptic plasticity mediated by the endocannabinoid system in 
hippocampus. 
 
Introduction 
Endocannabinoids (eCBs) have emerged as important regulators of synaptic 
plasticity in the brain (reviewed in Chevaleyre et al. 2006). Endocannabinoids are thought 
to predominantly mediate presynaptic inhibition of transmitter release via retrograde 
signaling. Depolarization-induced suppression of inhibition (DSI), described originally in 
cerebellum (Llano et al., 1991) and hippocampus (Pitler and Alger, 1992) is mediated by 
eCBs via transient presynaptic inhibition of GABA signaling (Kreitzer and Regehr, 
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2001b; Ohno-Shosaku et al., 2001; Wilson et al., 2001; Wilson and Nicoll, 2001). A 
similar form of short-term plasticity, depolarization-induced suppression of excitation 
(DSE), also involves eCB-dependent presynaptic inhibition of glutamatergic signaling via 
cannabinoid receptors present on glutamatergic terminals (Hajos et al., 2001; Kreitzer 
and Regehr, 2001b; Ohno-Shosaku et al., 2002b; Straiker and Mackie, 2005). eCB 
signaling is also implicated in long-term synaptic depression of inhibitory signaling in 
various brain regions including hippocampus (Chevaleyre and Castillo, 2003). This 
suppression of inhibitory signaling has been reported to facilitate induction of long-term 
potentiation (Carlson et al., 2002; Chevaleyre and Castillo, 2004).  
The CB1 receptor, which is believed to be responsible for the majority of CNS 
eCB effects, is abundantly expressed throughout the brain, with high levels of expression 
in hippocampus (Herkenham et al., 1990; Mackie, 2005). Immunohistochemical analysis 
shows that CB1 receptors are strongly expressed on synaptic terminals of 
cholecystokinin-containing (CCK) inhibitory interneurons in CA1 (Hajos et al., 2000; 
Katona et al., 2001; Katona et al., 2000; Katona et al., 1999; Marsicano et al., 2002; Tsou 
et al., 1999) and act to inhibit transmitter release (Hoffman, 2000; Kreitzer and Regehr, 
2001b; Levenes et al., 1998; Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2001). 
Recent data also suggests that CB1 receptors are present at low levels on excitatory 
presynaptic terminals (Hajos and Freund, 2002; Katona et al., 2006; Kawamura et al., 
2006; Takahashi and Castillo, 2006), and there is increasing evidence for a novel CB 
receptor in hippocampus that may affect glutamatergic synaptic transmission (Begg et al., 
2005; Lauckner et al., 2008; Mackie and Stella, 2006; Ryberg et al., 2007).  
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In the present study, we describe an eCB-dependent long-term potentiation (eCB-
LTP) of excitatory signaling at the hippocampal Shaffer collateral-CA1 synapse that is 
pharmacologically and mechanistically distinct from the NMDA receptor-dependent LTP 
that has been widely studied at this synapse. This potentiation of excitatory signaling is 
not mediated by inhibition of GABA signaling, suggesting that it represents a novel form 
of eCB-dependent synaptic plasticity.  
 
Experimental Methods 
Animals: Transverse hippocampal slices (400 !M) were prepared from Sprague Dawley 
rats of indicated ages in accordance with IACUC regulations. The animals were briefly 
anesthetized with isoflourane, decapitated, and the brains were rapidly removed and 
mounted for slicing. Slices were prepared using a vibrating microtome (VT1000S Leica, 
Germany) in ice-cold sucrose solution saturated with 95% O2 and 5% CO2 containing (in 
mM): 79.9 NaCl, 2.5 KCl, 70 sucrose, 1.25 NaH2Po4, 0.5 CaCl2, 7 MgCl2, 24.9 glucose, 
25.2 NaHCO3, 1.0 kynurenic acid.  Slices were stored in artificial cerebral spinal fluid 
(ACSF) containing (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 2.4 CaCl2, 1.2 NaH2PO4, 
11.4 glucose, and 21.4 NaHCO3 at 30°. 
 Electrophysiology: Slices were allowed to recover at least 1 hour before being placed in 
a submersion-type recording chamber perfused with 95% O2 and 5% CO2 -saturated 
ACSF. Recordings were performed at 30° C. Field excitatory postsynaptic potentials 
(fEPSPs) were evoked by 100 !s duration stimuli in stratum radiatum with a monopolar 
ACSF-containing glass pipette (2-3 M#). Stimulus strength (typically 50-100 !A) was 
adjusted to elicit responses 30-40% of maximum, and a stable baseline was maintained 
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for at least 20 minutes prior to initiation of an experiment. Responses were monitored at 
0.05 Hz. The 10 Hz stimulation protocol consisted of 2 trains of 100 pulses given at 10 
Hz, 20 seconds apart (Chevalayre and Castillo, 2004). Theta burst stimulation consisted 
of 10 trains of 5 pulses at 100 Hz with a 200 mS inter-burst interval, repeated once after a 
5 second delay. fEPSPs were recorded with Axoclamp or Geneclamp amplifiers 
(Molecular Devices, Sunnyvale CA) interfaced to Macintosh G4 or Pentium computers 
via Digidata 1320s using Axograph X (Axograph) or pClamp9 (Axon Instruments) 
acquisition and analysis software, respectively. Data were digitized at 5 kHz and filtered 
at 2 kHz. 
Drugs: All drugs, except SR141716 which came from NIDA (Bethesda, MD), were 
obtained from Tocris-Cooksin (Ellisville, Missouri) and prepared daily from concentrated 
(>1000x) stock solutions made as specified by the manufacturer. 
Statistical analysis: Data are normalized as a percentage of the baseline fEPSP amplitude 
(fEPSP slope analysis provided similar results) and presented as means ± standard errors 
unless otherwise stated. Students t-tests for unpaired data, accompanied by Levene’s test 
for equal variance, were used to compare the last 10 minutes of stable responses 
following 10 Hz and/or theta burst stimulation among the various conditions. 
 
Results 
10 Hz stimulation induces a long-lasting fEPSP potentiation  
Using a moderate frequency stimulation protocol (2 bouts of 100 pulses delivered 
at 10 Hz, 20 sec interburst interval), previously shown to elicit eCB-dependent iLTD 
without causing LTP (Chevaleyre and Castillo, 2004), we observed a transient depression  
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Figure 1: 10 Hz stimulation induces a long-term potentiation of hippocampal CA1 
fEPSPs, which is prevented by CB1 receptor ligands. 
 
A) Closed circles represent average normalized fEPSPs in control slices ± standard error (n=28), 
open circles are data from slices recorded in the presence of 2 !m AM251 (n=22), applied for 20 
minutes prior to 10Hz stimulation. Inset: traces from representative experiments showing change 
in fEPSP for each treatment group after 10 Hz stimulation (scale bars 400 !V by 20 mS).  
B) Closed circles represent average normalized fEPSPs in control slices ± standard error (n=28), 
open circles are data from slices recorded in the presence of 2 !m SR141716 (n=8).  
C) Summary of mean potentiation of fEPSP induced by 10 Hz and TBS stimulation in control 
slices (n=28, n=16 respectively), 2 !M AM251 (n=22, n=8), and 2 !M SR141716 (n=8). Both 
AM251 and SR141716 significantly inhibit 10 Hz potentiation (93.9 ± 4.0% in AM251 and 98.0 
± 2.5% in SR141716 versus 118±2.7% in control, p"0.01). TBS induced LTP is not affected by 2 
!m AM251 (158 +/-5.9%, n=8,versus 157 +/- 7.9%, n=16, in control conditions, p = 0.94)  
D) Application of the cannabinoid receptor agonist WIN55,212-2 (1 !M) depresses the fEPSP 
amplitude by 57 +/- 4.6 % and 10 Hz stimulation in the presence of WIN55,212-2  depresses the 
response an additional 20 +/- 4.0% (n=6) from the new baseline amplitude. Inset: PPR recordings 
from before (thin traces) and 45 minutes after (bold traces) WIN application. Traces on the left 
are normalized to the first fEPSP to reflect PPR changes (scale bars 10 mS by 200 !V). 
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followed by a persistent increase in fEPSP amplitude in 21-35 day old Sprague Dawley 
rats (Figure 1A). This potentiation (117.9% ± 2.7% of baseline, n=28) was seen in 21 of 
28 slices from 26 animals. We compared paired pulse ratio (PPR) measurements before 
and after 10 Hz stimulation, as changes in PPR can allude to changes in presynaptic 
neurotransmitter release probability. We found the baseline PPR to be 1.62 ± 0.03 (n=28) 
and following 10 Hz it was slightly reduced to 1.58 ± 0.03 (n=28, p=0.03). This reduction 
does correlate with an increased release probability; however, the small magnitude of 
change may not translate to physiological significance. With longer recording episodes 
the 10 Hz potentiation persisted for more than 3 hours (appendix A).  
Surprisingly, the 10 Hz LTP was completely blocked by the CB1 receptor 
antagonist AM251 at 2 !M (Figure 1 A, C; 93.9 ± 4.0 % of baseline fEPSP amplitude, 
n=22, p<0.001).  In contrast to its potent blocking effect on fEPSP potentiation induced 
by 10 Hz stimulation, AM251 had no effect on theta burst-induced LTP (158 ± 5.9% LTP 
in AM251 (n=8) versus 157 ± 7.9% LTP in control slices, n=16, p=0.94, Figure 1C). 
Cannabinoid receptor dependence was further substantiated by using a separate CB1 
antagonist, SR141716 (2!M), which also completely blocked the 10 Hz LTP (Figure 
1B,C: 98.0 ± 2.5% of baseline fEPSP amplitude, n=8, p<0.001).  
To further assess cannabinoid receptor involvement in this process, we tested the 
effect of 10 Hz stimulation in the presence of the CB1 agonist WIN55,212-2 (1 !M). 
Application of the agonist decreased the fEPSP amplitude by 57 ± 4.6 % in accordance 
with previously reported data (Al-Hayani and Davies, 2000; Hajos and Freund, 2002; 
Hajos et al., 2001; Hoffman et al., 2005; Misner and Sullivan, 1999; Takahashi and 
Castillo, 2006). 10 Hz stimulation in the presence of WIN55,212-2  did not induce 
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potentiation above the reduced baseline, but instead depressed the response an additional 
20 ± 4.0% (Figure 1D, n=6). Theta burst-induced LTP could still be induced in 
WIN55,212-2 although it was reduced compared to control conditions (appendix B). 
Taken together these results suggest that an endocannabinoid-dependent form of LTP, 
distinct from theta burst induced LTP, (eCB-LTP) is elicited by 10 Hz stimulation. 
 
10Hz-induced LTP is functionally distinct from theta burst-induced LTP  
LTP at the Shaffer-CA1 synapse can be readily elicited by theta burst stimulation 
and it requires activation of NMDARs (Malenka and Bear, 2004). Unlike typical TBS-
induced LTP, which is blocked by application of the NMDAR antagonist DL-AP5, the 
potentiation induced by10 Hz stimulation was not prevented by 50 !M DL-AP5 (Figure 2 
A,C; 113.3 ± 4.4% baseline fEPSP amplitude, n=13, p=0.37). At the same concentration, 
DL-AP5 completely blocked theta burst-elicited LTP (157 ± 7.9 % in control, n=16, and 
103 ± 2.9% in AP5 n=11, p"0.001). 
Because group I mGluRs have been shown to stimulate postsynaptic 
endocannabinoid release (Maejima et al., 2001; Ohno-Shosaku et al., 2002a; Varma et al., 
2001), we tested the effects of the mGluR1 antagonist LY367385 (30 !M) and the 
mGluR5 antagonist MPEP (10 !M). Similar to the effect of AP5, block of group I 
mGluRs did not significantly inhibit 10 Hz LTP (MPEP + LY367385: 114.2 ± 3.8%, 
n=9, p=0.5) (Figure 2B,C). Since group I mGluR and NMDARs both mediate 
intracellular Ca
2+
 increase and could potentially synergistically activate postsynaptic eCB 
synthesis, we tested the effect of blocking both receptors simultaneously. In the presence  
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Figure 2: 10 Hz LTP is blocked by co application of NMDA and group1 mGluR 
antagonists  
 
A) Averaged experiments showing 10 Hz stimulation induces eCB-LTP in the presence 
of 50 µM APV while TBS LTP is completely prevented (n=13).  
B) Averaged experiments showing group 1 mGluR receptor antagonists MPEP (10 µM) 
and LY367385 (30 µM) do not inhibit 10 Hz eCB-LTP (n=9).  
C) Summary of mean potentiation of fEPSP (% baseline) induced by 10 Hz stimulation 
in control conditions and the presence of different group 1 mGluR and NMDA receptor 
antagonists. eCB-LTP is inhibited by a combination of 10 µM MPEP, 30 µM LY367385, 
and 50 µM APV (100.3%±3.7%, n= 10, versus 118±2.7%, n=28, in control slices, 
p=0.002) Individual application of these inhibitors did not change the 10 Hz potentiation 
(10 µm MPEP  + 30 µm LY367385: 114.2±3.8%, n=9, p=0.50; 50 µm APV: 
113.3±4.4%, n=13, p=0.37) 
100
105
110
115
120
125
fE
P
S
P
 (
%
 b
a
s
e
li
n
e
)
c
o
n
tro
l 
M
P
E
P
 +
 L
Y
3
6
7
3
8
5
 
A
P
V
 
M
P
E
P
 +
 L
Y
3
6
7
3
8
5
 +
 A
P
V
 
60
80
100
120
140
160
0 10 20 30 40 50 60 70
fE
P
S
P
 (
%
 b
a
s
e
li
n
e
)
time (minutes)
10 Hz
MPEP + LY367385
Figure 2 
 * 
A 
B 
C 
60
80
100
120
140
160
180
0 10 20 30 40 50 60 70
fE
P
S
P
 (
%
 b
a
s
e
li
n
e
)
time (minutes)
50 µM APV
10 Hz
TBS
 23 
50 !M AP5, 30 !M LY367385 and 10 !M MPEP, 10 Hz stimulation failed to elicit eCB-
LTP (100 ± 3.7% baseline, n=10,p=0.002) (Figure 2C).  
 
GABA effects on eCB-LTP  
Endocannabinoid signaling in the hippocampus has been shown to result in 
presynaptic inhibition of GABA release (Hoffman, 2000; Kreitzer and Regehr, 2001b; 
Levenes et al., 1998; Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2001). To explore 
the possible role of GABA signaling in eCB-LTP, we compared the effect of 10 Hz 
stimulation in the presence and absence of the GABAA and GABAB receptor antagonists 
picrotoxin (100 !M) and CGP55845 (1 !M). Blockade of both GABAA and GABAB 
receptors did not reduce 10Hz-induced potentiation (126 ± 7.9%, n=9). Furthermore, in 
the presence of GABA antagonists, 10 Hz- LTP was still blocked by AM251(103 ± 3.5%, 
n=8, Figure 3 A,B). Together this data demonstrates that eCB-LTP is not a result of the 
inhibition of GABAergic signaling by CB1. 
Age dependence and saturation 
To better understand the characteristics of eCB-LTP we examined age 
dependence and it’s ability to saturate. We found eCB-LTP to be largely age dependent 
in the Sprague Dawley rats, with little to no potentiation occurring in older animals (42-
98 days post natal). In this age group, 10 Hz stimulation-induced LTP was only observed 
in 3 out of 14 slices (102 ± 3.3% of baseline, n=14; Figure 4A). Theta burst stimulation 
(TBS) reliably induced LTP in both age groups of animals (21-35 day old animals 157 ± 
7.9 % of baseline, n=16: 42-98 day old animals 140 ± 6.3% of baseline, n=11, p=0.14).  
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Figure 3: Inhibition of GABA signaling is not involved in eCB LTP. 
 
A) Averaged experiments showing 10 Hz stimulation induces eCB-LTP in the presence 
of the GABAA antagonist picrotoxin (100 µM) and the GABAB antagonist CGP55845 (1 
µM) (filled circles), which is blocked by the addition of 2 µM AM251 (open circles). 
B) Bar graph showing mean fEPSP (% of baseline amplitude) ± standard errors following 
10 Hz stimulation in control conditions (118 ± 2.7%, n=28), 100 µM picrotoxin (119 ± 
6.0%, n=10, p=0.88), 1 µM CGP55845 (114 ± 5.2%, n=9, p=0.45), 100 µM picrotoxin + 
1 µM CGP55845 (126 ± 7.9 %, n=9, p=0.25), 2 µM AM251, 100 µM picrotoxin, + 1 µm 
CGP55845 (103 ± 3.5%, n=8, p=0.01).    
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Figure 4: eCB-LTP is age dependent and saturable.  
 
A) Filled circles represent average normalized fEPSPs in 21-35 day SD rats ± standard 
error (n=28), open circles are data from 42-98 day old animals (n=14). Average fEPSP 
(% baseline) after 10 Hz stimulation in 21-35 day old animals is 118 ± 2.7% and is 102 ± 
3.3% in 42-98 day old animals. Inset -Summary of mean potentiation of fEPSP induced 
by 10 Hz stimulation in p21-35 (n=28) and p42-98 (n=14) SD rats.   
B) Representative experiment showing repeated application of the 10 Hz stimulation 
protocol causes saturable fEPSP potentiation, that does not occlude TBS-induced LTP 
(filled circles), and is blocked by 2µM AM251 (open circles) Inset - Averaged data 
showing mean saturated eCB-LTP reached after 1-4 repetitions of 10 Hz stimulation 
protocol (134 ± 3.2%, n=7) compared to 1 bout of 10 Hz (118 ±2.7%, n=28). 
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To further explore the mechanism of eCB-LTP we sought to verify that this form 
of long-term potentiation could be saturated and to test whether synapses that had 
reached a maximal level of eCB-dependent LTP could still undergo theta burst-induced 
LTP. We found that repeated pairings of 10 Hz stimulation increased fEPSP amplitudes 
to an average saturated level of 134 ± 3.8 % of baseline following 1-4 repetitions of the 
stimulus train (n=7; Figure 4B). Following maximal 10 Hz potentiation, theta burst 
stimulation further increased the fEPSP to a final level similar to what is achieved 
without prior 10 Hz stimulation (157 ± 9.5%; n=7, p=0.85; Figure 4B representative 
experiment, filled circles). The increases in fEPSP amplitude induced by repeated 10 Hz 
stimulation were also blocked by 2 µm AM251 while theta burst-induced LTP was not 
(Figure 4B, open circles). These data lend further support to the conclusion that eCB-LTP 
elicited by moderate frequency stimulation at the Shaffer-CA1 synapse is distinct from 
high frequency stimulus-induced NMDAR-dependent LTP.  
 
Discussion 
The major conclusion of this work is that a previously undescribed form of long-
term potentiation of excitatory synaptic transmission exists at Shaffer collateral-CA1 
pyramidal neuron synapses. This potentiation is mechanistically and pharmacologically 
distinct from the traditional NMDAR-dependent LTP extensively studied at this synapse 
(Malenka and Bear, 2004). It is induced by relatively short trains of moderate frequency 
stimulation (100 stimuli at 10 Hz, repeated once 20 s apart), and it appears to be 
endocannabinoid-mediated because it is blocked by the endocannabinoid receptor-
selective antagonists AM251 and SR141716. Also, the cannabinoid receptor agonist 
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WIN55,212-2 occludes potentiation. The 10 Hz LTP saturably increases with repeated 
bouts of stimulation, resulting in potentiation of fEPSP amplitudes exceeding 30%.  
The stimulation paradigm used here to elicit eCB-LTP is quite different from 
stimulus paradigms traditionally employed to study synaptic transmission and plasticity 
in the hippocampus (Bliss and Collingridge, 1993; Malenka and Nicoll, 1999). It is based 
on a stimulus pattern recently reported to elicit endocannabinoid-mediated LTD of 
GABA signaling in area CA1, which then facilitated subsequent TBS induction of LTP 
without directly potentiating excitatory synaptic transmission (Chevaleyre and Castillo, 
2004). Differences in the recording conditions may account for the different effects on 
excitatory transmission observed in that study and the present study; in particular it is 
possible that our recording conditions reflect recruitment of a somewhat larger ensemble 
of release sites. 
 Somewhat paradoxically, depression of Shaffer-CA1 excitatory transmission is 
seen with the exogenously applied cannabinoid agonist WIN 55,212-2 (Misner and 
Sullivan, 1999), and DSE has also been recorded at this synapse (Ohno-Shosaku et al., 
2002b).  However, with the moderate stimulation protocols we used, endocannabinoid 
actions may be spatiotemporally restricted to a subset of receptors that results in 
excitatory potentiation rather than suppression. 
Notably, hippocampal 10 Hz LTP is GABA independent, unlike previously 
reported eCB facilitation of HFS-induced LTP that involves suppression of GABAergic 
neurotransmission (Carlson et al., 2002; Chevaleyre and Castillo, 2004). Because we find 
that 10 Hz-induced AM251-sensitive potentiation still occurs in the presence of GABA 
receptor blockade, CB1 receptors on inhibitory interneurons are unlikely to be 
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responsible for eCB-LTP. Possible alternative mechanisms include direct modulation of 
glutamatergic transmission by CB1 or a related receptor, or modulation of other classes 
of inputs such as dopaminergic or cholinergic inputs. 
Interestingly, we found that eCB-LTP was age dependent in rats, being greatly 
decreased beyond 6 weeks of age. However, large developmental changes in CB1 
distribution have not been reported between adolescent and adult animals (Belue et al., 
1995; Morozov and F. Freund, 2003; Rodriguez de Fonseca et al., 1993). There is 
evidence for additional cannabinoid receptors in hippocampus (Begg et al., 2005; Hajos 
et al., 2001; Lauckner et al., 2008; Ryberg et al., 2007) but very little is known about 
their possible developmental regulation or expression levels. 
eCB-LTP appears to reflect a novel form of long-term potentiation of excitatory 
synaptic transmission in hippocampal area CA1. Further work will be required to more 
fully characterize the synaptic mechanisms, subtype and localization of receptors 
involved, and possible interactions with other forms of synaptic plasticity in this region. 
The properties of this form of long-term potentiation, which is elicited by moderate 
stimulation frequencies similar to those found in vivo, suggest that it may reflect an 
important mechanism by which endocannabinoids can influence excitatory synaptic 
plasticity. 
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CHAPTER 3 
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Abstract: 
Endocannabinoids (eCB) have emerged as important modulators of synaptic 
plasticity in recent years; however, their precise roles and mechanisms are not well 
understood and many contradictions exist in the current literature. We find that a 10 Hz 
stimulation protocol, which has been previously demonstrated to cause eCB release and 
inhibitory long-term depression (iLTD) (Chevaleyre and Castillo, 2004), produces lasting 
potentiation in the hippocampus that is greatly facilitated in CB1 receptor knockout mice 
and wild type mice treated with the CB1 antagonist SR141716. This research provides 
evidence supporting a role for the CB1 receptor as an inhibitor of long-term potentiation 
(LTP) induced by a moderate-frequency stimulation. Similar to traditional LTP, 10 Hz 
LTP is NMDA receptor mediated as it is completely blocked by the NMDA receptor 
antagonist APV in wild type and CB1 (-/-) mice. LTP induced by a higher frequency 
theta burst stimulation (TBS) protocol is not affected by CB1. Together, this data 
supports a role for the CB1 receptor in inhibiting the induction of LTP at low levels of 
activity. This could be very important in physiological conditions since low frequency 
neuron firing likely occurs in the brain in vivo. 
 
Introduction: 
  The endocannabinoid (eCB) system has recently emerged as an important 
modulator of synaptic plasticity (Chevaleyre et al., 2006). Endocannabinoids mainly act 
as retrograde messengers, traveling from their postsynaptic origin and targeting 
presynaptic receptors, which exert their effects largely by inhibiting neurotransmitter 
release in many brain structures. Currently, the most thoroughly characterized 
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endocannabinoids are 2-arachidonyl glycerol (2-AG) and anandamide (AEA), both of 
which are postsynaptically synthesized from membrane bound lipid precursors (Devane 
et al., 1992; Mechoulam et al., 1995; Stella et al., 1997; Sugiura et al., 1995). The 
endocannabinoids exert their effects through at least two cloned and widely accepted 
endocannabinoid receptors, CB1 (Matsuda et al., 1990) and CB2 (Munro et al., 1993). 
CB2 is almost exclusively located in the immune system (Axelrod and Felder, 1998; 
Pertwee, 1997), while CB1 is the primary receptor in the CNS. Both receptors are G-
protein coupled and CB1 is one of the most highly expressed GPCRs in the brain 
(Herkenham et al., 1990). The CB1 receptor is thought to be responsible for most 
endocannabinoid actions in the brain although there is strong evidence for a third 
cannabinoid receptor that may also play important roles in neuronal signaling and 
plasticity (Begg et al., 2005; Lauckner et al., 2008; Mackie and Stella, 2006; Ryberg et 
al., 2007).  
CB1 receptors are highly expressed in structures known to be important for 
learning and memory, including the cerebellum, cortex, amygdala, and hippocampus 
(Freund et al., 2003; Herkenham et al., 1990). The hippocampus, which is a major center 
for spatial learning and memory formation (Eichenbaum, 2004; Squire et al., 2004), has a 
very high concentration of CB1 receptors (Herkenham et al., 1990; Mackie, 2005). The 
majority of research demonstrates that CB1 is localized to cholecystokinin (CCK) 
GABAergic interneurons, where it acts to inhibit GABA release (Hajos et al., 2000; 
Katona et al., 2001; Katona et al., 2000; Katona et al., 1999; Marsicano and Lutz, 1999; 
Marsicano et al., 2002; Tsou et al., 1999), likely by direct interference with calcium 
channel operation (Shen and Thayer, 1998; Sullivan, 1999; Twitchell et al., 1997). The 
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effect of CB1 receptors on GABAergic neurons is important for at least two forms of 
synaptic plasticity, depolarization-induced suppression of inhibition (DSI) (Kreitzer and 
Regehr, 2001a; Llano et al., 1991; Ohno-Shosaku et al., 2001; Pitler and Alger, 1992; 
Wilson et al., 2001; Wilson and Nicoll, 2001) and inhibitory long-term depression 
(iLTD) (Chevaleyre and Castillo, 2004). In both DSI and iLTD presynaptic GABA 
release is inhibited through CB1 receptor activation causing a localized disinhibition. 
Several papers have supported a role for CB1 in the facilitation of LTP, likely through 
this mechanism. Chevaleyre and Castillo (2004) showed that induction of iLTD 
facilitated greater LTP at the same recording site when compared to sites that did not 
undergo iLTD. Similarly, it has also been reported that CB1 activation during DSI 
allowed LTP induction with stimulus protocols that were normally ineffective (Carlson et 
al., 2002). These data fit with the currently accepted mechanism of action of CB1 in 
hippocampus.  
Despite the view that CB1 only acts on inhibitory interneurons and regulates 
GABA release, there is accumulating evidence supporting a role for CB1 in the 
modulation of excitatory signaling in hippocampus. The effect of the cannabinoid 
receptor agonist WIN55,212-2 on excitatory signaling supports this. Several papers show 
that WIN55,212-2 application depresses excitatory signaling, as seen by a decrease in 
EPSP amplitude and increased paired pulse ratio. This phenomena does not occur in 
CB1(-/-) animals and can be reversed by application of CB1 antagonists (Hoffman et al., 
2005; Misner and Sullivan, 1999; Takahashi and Castillo, 2006). WIN55,212-2 also 
depresses IPSP amplitude, supporting CB1’s known actions on GABAergic neurons 
(Hajos and Freund, 2002; Hoffman and Lupica, 2000). Aside from the WIN55,212-2 
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data, several other pieces of evidence suggest that CB1 can affect glutamatergic 
signaling. CB1 mRNA has been found in CA3 pyramidal cells, whose axons make up the 
Schaffer collaterals that synapse on CA1 pyramidal cell dendrites in the stratum radiatum 
(Marsicano et al., 2003). Also, the enzymatic machinery responsible for the synthesis of 
eCB has also been found in glutamatergic inputs (Nyilas et al., 2008).  
Similarly there are multiple papers that show a role of CB1 in inhibition of 
excitatory long-term potentiation. The CB1 agonist WIN55,212-2 and the endogenous 
ligand 2-AG have been shown to block LTP (Misner and Sullivan, 1999; Stella et al., 
1997). In the cortex, it was reported that CB1 activation shifts synapses in favor of LTD 
induction while CB1 block shifts them towards LTP induction (Auclair et al., 2000). 
Slanina et al (2005) showed that CB1 inhibited LTP induced with moderate trains of 
stimulations, short 100 Hz bursts, and theta burst stimulation, but did not affect LTP 
induced with robust high frequency stimulation protocols. Chronic THC exposure has 
been shown to inhibit both HFS and TBS induced LTP, which can be reversed by co-
administration of AM251. Interestingly this study also found that chronic CB1 block with 
AM251 enhanced TBS LTP but not HFS LTP (Hoffman et al., 2007). Several behavioral 
studies also support a role for CB1 in LTP inhibition. Hill et al (2004) found that the CB 
agonist HU-210 initially impaired water maze performance and LTP induction in-vivo. 
Similarly, another group found spatial learning deficits and suppression of hippocampal 
pyramidal cell firing in rats treated with the CB1 agonist HU-210 (Robinson et al., 2007).   
In this study we add to the accumulating data supporting a role for CB1 LTP 
inhibition. We use a moderate frequency 10 Hz LTP induction protocol, described by 
Chevaleyre & Castillo (2004) to induce eCB release and cause iLTD, to induce a NMDA 
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receptor dependent LTP, which is inhibited by CB1 receptor activation. In addition, we 
find that CB1 affects the ability to induce LTD, and we present data supporting the 
existence of a novel cannabinoid receptor. 
 
Experimental Methods 
Animals: Transverse hippocampal slices (350 !M) were prepared from C57BL/6 wild 
type or CB1(-/-) mice of indicated ages in accordance with IACUC regulations. CB1(-/-) 
mice (a generous gift from Drs. Marsicano and Lutz, Germany) were backcrossed onto 
the C57Black6 background (Zimmer et al., 1999). At the time of the experiments, all 
mouse pups were 21-35 days old with the exception of the LTD experiments: these mice 
were 14-21 days old. The animals were briefly anesthetized with isoflourane, decapitated, 
and the brains were rapidly removed and mounted for slicing. Coronal slices were 
prepared using a vibrating microtome (VT1000S and VT1200S Leica, Germany) in ice-
cold sucrose solution saturated with 95% O2 and 5% CO2 containing (in mM): 79.9 NaCl, 
2.5 KCl, 70 sucrose, 1.25 NaH2Po4, 0.5 CaCl2, 7 MgCl2, 24.9 glucose, 25.2 NaHCO3, 1.0 
kynurenic acid.  Slices were stored in artificial cerebral spinal fluid (ACSF) containing 
(in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 2.4 CaCl2, 1.2 NaH2PO4, 11.4 glucose, and 21.4 
NaHCO3 at 30° C. 
 Electrophysiology: Slices were allowed to recover at least 1 hour before being placed in 
a submersion-type recording chamber perfused with 95% O2 and 5% CO2 saturated 
ACSF. Recordings were performed at 30° C. Field excitatory postsynaptic potentials 
(fEPSPs) were evoked by 100 !s duration stimuli in stratum radiatum with a monopolar 
ACSF-containing glass pipette (2-3 M#). Stimulus strength (typically 50-100 !A) was 
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adjusted to elicit responses 30-40% of maximum for LTP experiments and 60-70% of 
maximum for LTD experiments.  A stable baseline was maintained for at least 20 
minutes prior to initiation of an experiment. Responses were monitored at 0.05 Hz. The 
10 Hz stimulation protocol consisted of 2 trains of 100 pulses given at 10 Hz, 20 seconds 
apart (Chevaleyre and Castillo, 2004). Theta burst stimulation consisted of 10 trains of 5 
pulses at 100 Hz with a 200 mS inter-burst interval, repeated once after a 5 second delay. 
5 Hz stimulation consisted of 2 trains of 100 pulses given at 5 Hz, 20 seconds apart. The 
LFS-PPR LTD stimulation protocol consisted of 1200 paired pulse stimulations, 50 mS 
interpulse interval, delivered at 1 Hz. fEPSPs were recorded with Axoclamp or 
Geneclamp amplifiers (Molecular Devices, Sunnyvale CA) interfaced to Macintosh G4 
or Pentium computers via Digidata 1322s using Axograph X (AxographX, Dr. John 
Clements) or pClamp9 (Axon Instruments) acquisition and analysis software, 
respectively. Data were digitized at 5 kHz and filtered at 2 kHz. 
Drugs: All drugs were obtained from either Tocris-Cooksin (Ellisville, Missouri) or 
Ascent Scientific (Weston-Super-Mare, UK) and prepared daily from concentrated 
(>1000x) stock solutions made as specified by the manufacturer. 
Statistical analysis: Data are normalized as a percentage of the baseline fEPSP amplitude 
and presented as means ± standard errors unless otherwise stated. Students’ t-tests for 
unpaired data, accompanied by Levene’s test for equal variance, were used to compare 
the last 10 min of stable responses following the stimulation protocols with various drug 
treatments. 
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Results 
CB1 receptor inhibits long-term potentiation induced by moderate-frequency 
stimulation but not theta burst stimulation. 
  We found that a 10 Hz stimulation protocol (2 bursts of 100 pulses delivered at 
10 Hz, 20 sec interburst interval), previously shown to elicit eCB-dependent iLTD 
without directly inducing LTP (Chevaleyre and Castillo, 2004) induced a transient 
depression followed by a persistent 117.9 ± 2.1% (n=44) potentiation of fEPSP amplitude 
in C57 Black6 wild type mice (Figure 1A,D). The potentiation, referred to as 10 Hz LTP, 
was seen in 33 of 44 experiments. In CB1(-/-) mice 10 Hz stimulation caused a much 
greater potentiation when compared to wild type mice (138.0 ± 4.6%, n=24, p< 0.001, 
Figure 1A,D), and was seen in 23 out of 24 experiments. The increased 10Hz LTP was 
mimicked by the application of CB1 antagonist SR141716 (1 !M) in wild type mice 
(144.3 ± 12.0%, n=9, p = 0.05, Figure 1B,D). Application of 1 !M SR141716 alone did 
not change the fEPSP amplitude (appendix C). Also, during the 10 Hz stimulation, fEPSP 
amplitudes from CB1 (-/-) mice and wild type mice in the presence of SR141716 were 
not elevated above control fEPSPs, suggesting the increased potentiation does not occur 
until after the stimulus train is complete (appendix D). LTP induced by the more robust 
theta burst stimulation (TBS) was not statistically different between wild type and CB1(-
/-) mice (148.4 ± 5.8%, n=7; 147.0 ± 11.9%, n=4, p=0.90, Figure 1C,D).  
We also compared paired pulse ratio (PPR) measurements in wild type and CB1(-
/-) animals, as changes in PPR can elude to changes in presynaptic neurotransmitter 
release probability. The basal PPR was slightly lower in the CB1(-/-) mice 
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Figure 1: CB1 inhibits 10 Hz induced LTP, but not theta burst induced LTP  
 
A) 10 Hz stimulation (2 trains of 100 pulses at 10 Hz, 20 s apart) induced a lasting 117.9 
± 2.1% of baseline potentiation of the fEPSP in wild type C57Black6 mice (n = 44) and 
in CB1(-/-) mice it causes a 138.0 ± 4.6% potentiation (n = 24), (p<0.001).  
B) Enhanced 10 Hz LTP is achieved in wild type mice by application of the CB1 receptor 
antagonist SR141716 (1 µm). (144.3±12.0%, n = 9 versus 117.9±2.1%,n = 44, p = 0.05). 
C) TBS causes a lasting 148.4± 5.8% potentiation of the fEPSP in wild type C57Black6 
mice (n = 7) and a 147.0 ± 11.9% potentiation of the fEPSP in CB1(-/-) mice (n = 4). 
TBS LTP in the wild type and CB1(-/-) mice are not significantly different (p = 0.90). 
D) Bar graph showing average fEPSP increases in wild type, CB1(-/-), and wild type with 
SR141716 application following 10 Hz and TBS stimulation. Inset: representative traces 
showing fEPSPs at baseline (thin trace) and 40 minutes post 10 Hz stimulation (bold 
trace) in wild type, CB1(-/-), and wild type with 1 µm SR141716 respectively (scale bars 
5 ms by 0.1 mV). 
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(1.65 ± 0.04, n=33) compared to the wild type mice (1.75 ± 0.03, n=21, p=0.05). This 
suggests that the CB1(-/-) mice have an increased presynaptic release probability and 
perhaps CB1 receptors cause a tonic level of presynaptic inhibition in wild type mice. 
Following 10 Hz stimulation, the PPR of wild type mice did not significantly change 
(1.71 ± 0.03, n=30, p=0.11). However, in the CB1(-/-) mice the PPR following 10 Hz 
stimulation did significantly decrease (1.52 ± 0.05 post 10 Hz, n=21, p<0.01, Appendix 
E). Similarly, PPR following 10 Hz stimulation in the presence of 1 !m SR141716 also 
significantly decreased (baseline PPR = 1.78 ± 0.11, post 10 Hz in SR141716 PPR = 1.62 
± 0.09, n=8, p = 0.02), although the application of SR141716 alone did not change PPR 
(1.80 ± 0.12, n=8, p=0.39). Together, this data supports an increased presynaptic release 
probability as one of the mechanisms responsible for the observed 10 Hz LTP.  
 
WIN55,212-2 inhibits 10 Hz LTP 
To further assess the involvement of CB1 in 10 Hz LTP, we tested the effect of 
the CB1 agonist WIN55,212-2 (1 !M) on basal recording and 10 Hz stimulation in wild 
type and CB1(-/-) mice. Application of agonist decreased the fEPSP amplitude in the 
wild type mice to 43.7 ± 4.5% of baseline (n=6) and increased paired pulse ratio from 
1.76 ± 0.12 to 2.07 ± 0.10 (n=6, p<0.01) (Figure 2 A,B) in accordance with previous 
observations (Al-Hayani and Davies, 2000; Hajos and Freund, 2002; Hajos et al., 2001; 
Hoffman et al., 2005; Misner and Sullivan, 1999; Takahashi and Castillo, 2006). 
WIN55,212-2 had no effect on fEPSP amplitude (99.0 ± 4.4%, n=9, p=0.97) or paired 
pulse ratio (base PPR = 1.67 ± 0.06, WIN PPR = 1.70 ± 0.08, n=9, p=0.43; Figure 2A,B) 
in CB1(-/-) mice. In both wild type and CB1(-/-) mice WIN55,212-2 blocked 10 Hz LTP 
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Figure 2: CB agonist WIN55,212-2 prevents 10 Hz LTP in wild type mice and CB1(-/-) 
mice.  
 
A) Application of 1 µM WIN55,212-2 causes a lasting depression of the fEPSP in wild 
type (43.7 ± 4.5% of baseline, n=6), but not CB1(-/-) mice (99.0 ± 4.4% of baseline, 
n=9). 10 Hz stimulation does not cause potentiation of the fEPSP above the baseline 
established in WIN55,212-2 in wild type and CB1(-/-) mice (105.6 ± 4.5%, p=0.26, n=6; 
103.0 ± 9.8%, p= 0.76, n=9 respectively).  
B) Representative traces showing the effect of 1µM WIN55,212-2 on fEPSP amplitude 
(left traces) and paired pulse ratio (right traces, normalized to the amplitude of the first 
pulse) in CB1(-/-) and wild type mice. Black traces represent baseline fEPSP before WIN 
application and gray traces show the fEPSP after 45 minutes of WIN application. Inset - 
average paired pulse ratio for CB1(-/-) and wild type animals, baseline and in 1 µM 
WIN55,212-2. CB1(-/-) baseline ppr 1.67 ± 0.064, WIN ppr 1.70 ± 0.080 n=9, p =0.43; 
wild type baseline ppr = 1.76 ± 0.12, WIN ppr = 2.07 ± 0.10, n=6, p=.008. 
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 (wild type, 105.6 ± 4.5%, p=.026, n=6; CB1(-/-), 103.0 ± 9.8%, p=.76, n=9; Figure 2A). 
This data supports a role for CB1 in 10 Hz LTP, but also points to the possibility that an 
additional endocannabinoid receptor, which WIN55,212-2 also binds, may be modulating 
synaptic plasticity. 
 
10 Hz LTP is NMDA receptor dependent 
Our next step was to determine if 10 Hz LTP is NMDA receptor dependent. 
Similar to TBS induced LTP, 10 Hz LTP was completely blocked by the NMDA receptor 
antagonist APV (50 !M) in both wild type and CB1(-/-) mice (103.0 ± 3.8 %, n=5; 100.0 
± 2.3%, n=8, Figure 3 A,B). Thus 10 Hz LTP, like traditional LTP, requires NMDA 
receptor activation and likely shares common expression mechanisms. 
 
LTP threshold and LTD 
Since both the magnitude and success rate of 10 Hz LTP was increased in the 
CB1(-/-) mice we wanted to assess whether there was a difference in the stimulus 
threshold required to induce fEPSP potentiation between CB1(-/-) and wild type mice. 
Initially we tried a 5 Hz stimulation protocol (2 bouts of 100 pulses at 5Hz, 20 s apart) 
and found no difference between wild type and CB1(-/-) mice, with each group showing 
a slight potentiation (CB1(-/-) 107.7 ± 5.2% n=8; wild type 112.2 ± 3.1% n= 9; p=0.46, 
Figure 4A). Interestingly, both groups of animals exhibited the same transient depression 
that we observed following 10 Hz stimulation in wild type mice, suggesting that the 
mechanisms behind this depression are not CB1 mediated.  Next, we tried a less intense 
10 Hz stimulation that had 100 pulses instead of 200 (10 Hz(1), 100 pulses at 10 Hz, no 
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Figure 3: 10 Hz LTP is NMDA receptor dependent in both wild type and CB1(-/-) mice. 
 
A) Application of the NMDA receptor antagonist APV (50 µM) for 20 minutes inhibits 
10 Hz LTP in wild type mice (103.2 ± 3.8% increase, n = 5, p=0.45 compared to 
baseline). 
 B) 50 µM APV also inhibits 10 Hz LTP in CB1(-/-) mice (100.0 ± 2.3% increase, n = 8, 
p=0.95 compared to baseline). There is no significant difference between the wild type 
and knockout following 10 Hz stimulation in APV (p = 0.45). 
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Figure 4: CB1 doesn’t change potentiation with lower stimulus protocols but does 
affect the frequency of LTD induction.  
 
A) 5 Hz stimulation (2 bouts of 100 pulses at 5 Hz, 20 s apart) does not cause LTP in 
either CB1(-/-) (filled circles) or wild type (open circles) mice and there is no difference 
between the groups following 5 Hz, CB1(-/-) 107.7 ± 5.2% n=8; wild type 112.2 ± 3.1% 
n=9; p=0.46.  
B) A less intense 10 Hz stimulation protocol (100 pulses at 10 Hz, no repetitions) also 
does not cause significant differences between wild type and CB1(-/-) animals although 
the trend supports CB1 somewhat inhibiting potentiation (CB1(-/-) 116.8 ± 9.3% n=8; 
wild type 105.6 ± 1.7% n=8; p=0.27).  
C)1 Hz paired pulse stimulation (50 mS inter-pulse interval) for 20 min (1200 paired 
pulses) (LFS-PPR) depresses the fEPSP 15 ± 2.4% in C57Black6 wild type mice (n = 6) 
and 16 ± 4.5% in CB1(-/-) mice (n = 4). Only successful LTD experiments are plotted 
and  there is no difference in LTD magnitude (p = 0.15).  
D) The frequency of successful LTD induction was different between wild type and 
CB1(-/-) animals. In wild type mice LTD was successfully induced in 6 out of 7 attempts 
(86%) and in CB1 (-/-) mice LTD was successful in 4 out of 8 attempts (50%). 
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repetitions). Again, there was no significant difference between the wild type and CB1(-/-
) mice and each group showed a slight potentiation(CB1(-/-), 116.8 ± 9.3 %, n=8; wild 
type, 105.0 ± 2.2%, n=6; p=0.25, Figure 4B). None the less, the trend followed our earlier 
10 Hz LTP data, with CB1(-/-) animals experiencing a greater increase than the wild type 
animals. Although the lower frequency stimulations do not reveal a CB1 mediated 
threshold effect the subtle differences we observe do support CB1s inhibition of 
potentiation. 
Finally, we wanted to investigate if CB1 had an effect on the opposing form of 
synaptic plasticity, long-term depression (LTD). We used a low frequency paired pulse 
protocol (LFS-PPR), which consisted of 1200 paired pulses (50 mS interpulse interval) 
administered at 1 Hz to induce LTD.  Although there were no differences in the level of 
LTD achieved during successful experiments (wild type, 85.5 ± 2.4 %, n=6; CB1(-/-), 
84.8 ± 4.5%, =4; p=0.88), we did find that the frequency at which successful LTD 
(defined as at least a 5% depression sustained for 40 minutes post LFS-PPR) occurred 
was different. In wild type mice we had a 85.7% success rate (6 out of 7 successful 
attempts) in achieving LTD; however in CB1(-/-) mice our success rate was only 50.0% 
(4 out of 8 successful attempts, Figure 4C,D). This data supports a role for CB1 in 
facilitating LTD induction, which correlates with CB1s inhibition of long-term 
potentiation 
 
Discussion 
As the major result of this work we show that the CB1 receptor acts to inhibit 
LTP induced by moderate-frequency stimulation through the use of CB1 receptor 
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knockout mice and standard electrophysiological techniques in acute hippocampal slices. 
The 10 Hz stimulation protocol we used, which was previously described by Chevaleyre 
and Castillo (2004) to induce endocannabinoid release and cause iLTD without inducing 
LTP, in fact caused a lasting potentiation in C57Black6 wild type mice. This 10 Hz LTP 
is greatly increased with pharmacological blockade or genetic removal of the CB1 
receptor. Our results are in contrast to Chevaleyre and Castillo’s data in that they found 
10 Hz stimulation did not potentiate fEPSPs; however, differences in the experimental 
conditions, such as species used and recording set up, may account for these 
inconsistencies. Also, we found that while 10 Hz induced LTP was increased in CB1 
knockout mice, LTP caused by higher frequency theta burst stimulation was not altered. 
Additionally, it is important to note that the LTP induced by 10 Hz stimulation is likely 
controlled by the same mechanisms as traditional TBS or HFS induced LTP as it is 
NMDA receptor dependent.   
We also found that the cannabinoid receptor agonist WIN55,212-2, which causes 
a significant depression of fEPSPs in wild type but not CB1(-/-) mice, completely 
prevented 10 Hz potentiation. While we predicted that WIN55,212-2 application would 
occlude potentiation in wild type animals we were surprised by the result in CB1 
knockout mice. WIN55,212-2 blockade of 10 Hz LTP in CB1(-/-) mice supports the 
existence of another cannabinoid receptor that may have important roles in synaptic 
plasticity, and as evidence continues to accumulate in the favor of an additional 
cannabinoid receptor this finding could be of key importance (Begg et al., 2005; 
Lauckner et al., 2008; Mackie and Stella, 2006; Ryberg et al., 2007). Previous studies 
showing an inhibitory effect of WIN55,212-2 on synaptic plasticity have concentrated on 
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wild type animals and not CB1(-/-) mice so it is possible that past results could be 
partially attributed to the agonists effects on another cannabinoid receptor (Auclair et al., 
2000; Levenes et al., 1998; Misner and Sullivan, 1999; Paton et al., 1998).  
We next tested whether the threshold for LTP induction was shifted in CB1 (-/-) 
mice by using two less intense stimulation protocols. With 5 Hz stimulation we did not 
achieve significant potentiation in either wild type or CB1 knockout mice. We did note 
however that a transient depression, similar to that observed in wild type mice with 10 Hz 
stimulation, occurred in both the CB1 knockout and wild type animals. This leads us to 
believe that the depression following 10 Hz stimulation is not mediated by the CB1 
receptor. Further work will be required to determine what is causing the transient 
depression as it was observed in all of our treatments with varying frequency and 
magnitude.  A less intense 10 Hz protocol also did not reveal significant differences 
between wild type and CB1(-/-) animals, but the trend did support CB1 receptor’s 
inhibition of LTP, as the small potentiation achieved following stimulation in CB1(-/-) 
mice was slightly larger than what was observed in wild type mice. Thus, although we 
did not find evidence for a clear CB1 mediated shift in LTP induction threshold our data 
still supports a role for CB1 in inhibition of potentiation. 
 Several other papers have found CB1 activation to inhibit LTP; however, there 
are differences in experimental conditions, mainly that these studies used higher 
frequency stimulation protocols, relied on pharmacological tools, and/or did not have use 
of the CB1 knockout mice (Collins et al., 1994; Misner and Sullivan, 1999; Nowicky et 
al., 1987; Stella et al., 1997; Terranova et al., 1995). Two more recent papers have found 
CB1 to inhibit LTP induced by lower frequency stimulation, without affecting high 
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frequency induced LTP (Hoffman et al., 2007; Slanina et al., 2005). Interestingly both 
these papers found TBS induced LTP to be inhibited but not 100 Hz high frequency 
stimulation (HFS). The TBS protocol used by Slanina et al (2005) was quite different 
from ours in that they used 5 bursts of 4 pulses at 100 Hz, 200 ms apart, repeated once 
after 5 seconds. Our protocol used 10 bursts of 5 pulses at 100 Hz, 200 ms apart, repeated 
once after 5 seconds. Thus, their TBS protocol was actually a less intense stimulation so 
their results may be closer to what we observed with the 10 Hz stimulation. There were 
also notable differences in experimental conditions, one major point being that they used 
rats instead of mice.  
The experiments done by Hoffman et al (2007) also were completed in rats and 
used chronic !9-THC administration in living animals that were then used to prepare 
acute hippocampal slices. Although the theta burst protocol they used was the same as 
ours the difference in experimental setup could largely account for differences in results. 
Also, by administering !9-THC chronically they could be activating non-CB1 
cannabinoid receptors, which also could affect plasticity. Overall, there is accumulating 
evidence to suggest that CB1 inhibits long-term potentiation and may have a larger effect 
on plasticity induced by lower levels of activity. This is hugely important as the high 
frequency stimulations used in many plasticity studies are less likely to occur naturally 
and lower frequency stimulations, such at theta rhythms, have been observed in vivo. 
Just as we found CB1 receptor activation to inhibit LTP, we also found that it 
increased the success rate of LTD. In wild type mice we were able to successfully induce 
LTP in 86% of attempts; however, LTD induction was more difficult in CB1(-/-) mice, 
with success in only 50 % of attempts. This data supports our earlier findings and helps to 
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show just how important CB1 is as a modulator of synaptic plasticity. Auclair et al (2000) 
(Auclair et al., 2000) described a similar phenomenon using cortical recordings. They 
found that in synapses where tetanic stimulation equally induced either LTP or LTD 
application of WIN55,212-2 shifted plasticity towards LTD, whereas application of 
SR141716 shifted plasticity in favor of LTP.  
Our results point to a very important role for endocannabinoids in modulating 
synaptic plasticity. We show evidence in support of CB1 modulating excitatory signaling, 
in particular by inhibiting LTP. Perhaps CB1 is directly inhibiting presynaptic glutamate 
release as our results cannot be explained by the known inhibition of GABA release 
typically associated with CB1 receptor activation. The differences we observed in paired 
pulse ratio (PPR) also support this idea as PPR was increased in the wild type mice 
relative to the CB1(-/-) mice. This suggests a decreased release probability when CB1 is 
present and active. Further work will be required to understand the mechanisms by which 
LTP is inhibited. It will also be important to look for what roles the non-CB1 receptor has 
in synaptic plasticity once it is well characterized. 
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CHAPTER 4: DISCUSSION 
A moderate frequency induced LTP modulated by endocannabinoids was studied 
in rats and mice. We found that a 10 Hz stimulation protocol previously shown to cause 
endocannabinoid release and iLTD without potentiating excitatory inputs (Chevaleyre 
and Castillo, 2004), actually causes significant potentiation of fEPSPs in rat and mouse 
hippocampal slice recordings, with some key differences occurring between species. 
 
10 Hz LTP requires cannabinoid receptor activation in rats 
The results presented in the first manuscript describe how, in Sprague Dawley 
rats, 10 Hz induced LTP is different from previously described forms of LTP. Most 
notably it is distinct from traditional NMDA receptor dependent LTP in that it requires 
cannabinoid receptor activation but not NMDA receptor activation. We found that two 
different CB1 receptor antagonists prevented the 10 Hz LTP as did the cannabinoid 
receptor agonist WIN55,212-2 . 10 Hz LTP was still viable when NMDA receptors were 
blocked, but higher frequency LTP, which is known to be NMDA receptor dependent, 
was completely prevented.  
Our findings also support known mechanisms for endocannabinoid synthesis. 
When both NMDA receptors and group1 mGluR receptors are blocked, 10 Hz LTP is 
prevented. As both NMDA and group1 mGluR receptor activation serve to independently 
increase intracellular calcium, their dual inhibition could prevent sufficient rises in 
calcium levels, thereby blocking eCB synthesis (Cadas et al., 1996; Di Marzo et al., 
1994; Stella and Piomelli, 2001; Stella et al., 1997). 
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Initially, we believed that 10 Hz LTP could be explained by CB1’s known actions 
of inhibiting GABAergic signaling, which has been reported to occur following 10 Hz 
stimulation (Chevaleyre and Castillo, 2004). However, we were surprised to find that 
when GABAergic inputs were pharmacologically blocked 10 Hz LTP remained intact 
and was still prevented by cannabinoid receptor antagonists. This suggested a novel 
signaling pathway that does not require GABAergic signaling suppression is responsible 
for 10 Hz LTP.  Possible alternative mechanisms for causing 10 Hz LTP include direct 
modulation of glutamatergic transmission by CB1 or a related receptor, or modulation of 
other classes of inputs such as dopaminergic or cholinergic inputs. It will be important to 
explore these avenues in future research.  
10 Hz LTP in rats also exhibits age dependence, with older animals (42-98 days 
post natal) failing to achieve potentiation. Developmental changes in CB1 receptor 
distribution do not explain why this occurs as large changes in expression between 
adolescent animals (post natal day 21-35) and adults have not been reported (Belue et al., 
1995; Morozov and F. Freund, 2003; Rodriguez de Fonseca et al., 1993). However, if 
another cannabinoid receptor is important for 10 Hz LTP, there could be age dependent 
changes in its distribution which would more aptly coincide with our phenomena. 
Overall, in rats we have described a novel form of LTP in hippocampus that is induced 
by moderate frequency stimulation and modulated by endocannabinoid signaling. 
 
In mice, CB1 receptor activation inhibits long-term potentiation 
We initially studied the 10 Hz LTP in mice to show its conservation between 
species and, based on our results in rats, we predicted it would be eliminated in CB1 (-/-) 
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mice. However, a second manuscript developed from the very intriguing results we 
found.  Indeed, 10 Hz LTP was conserved in C57Blk6 mice and the potentiation was of a 
similar magnitude to what we observed in rats. The major difference we found was that in 
CB1 (-/-) mice 10 Hz stimulation roughly doubled the magnitude of LTP instead of 
preventing it as we had hypothesized. Application of a CB1 receptor antagonist 
mimicked these results in wild type mice.  Also, the 10 Hz LTP in both wild type and 
CB1(-/-) mice was NMDA receptor dependent, unlike our observations in the rats. There 
were no differences between the wild type and CB1(-/-) animals following theta burst 
induced LTP. In general, this suggests that in C57Black6 mice the CB1 receptor acts to 
inhibit LTP induced by moderate frequency stimulation.  
We also found that application of the CB1 agonist WIN55,212-2 blocked 10 Hz 
LTP in both wild type and CB1(-/-) mice. However, WIN55,212-2 application did not 
depress fEPSPs in the CB1(-/-) animals as it did in the wild type animals. This data 
supports the existence of another cannabinoid receptor that is also activated by 
WIN55,212-2 and is important for synaptic plasticity. Just as we found CB1 receptor 
activation to inhibit 10 Hz LTP, we also found that it increased the success of LTD. 
Perhaps CB1 is inhibiting presynaptic glutamate release as our results cannot be 
explained by the known inhibition of GABA release typically associated with CB1 
receptor activation. Our comparison of the paired pulse ratio (PPR) between wild type 
and CB1(-/-) mice supports this idea as we observed a lower PPR in CB1(-/-) mice, 
indicating an increased release probability.  Further work will be required to understand 
the mechanisms by which LTP is inhibited. It will also be important to look for what 
roles the non-CB1 receptor has in synaptic plasticity once it is better characterized. 
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Conclusion 
The endocannabinoid system plays important roles as a modulator of synaptic 
plasticity and exhibits some very important differences between species. This work may 
help to explain some of the contradictions in the current literature, as well as illustrate the 
importance of carefully characterizing any model systems being used in eCB 
experimentation. Unfortunately, we cannot explain why eCBs seem to play opposing 
roles in rats and mice. The current literature detailing CB1’s distribution shows a similar 
pattern between species, with few differences in CB1 expression in hippocampus (Haller 
et al., 2007; Morozov and F. Freund, 2003). Perhaps a more careful examination of the 
receptor localization and areas of endocannabinoid synthesis will help elucidate our 
findings. Also, identification and cloning of the novel cannabinoid receptor(s) will be of 
great importance as it’s localization and expression levels may differ between species. 
Overall, it is apparent that eCB signaling plays crucial roles in the modulation of 
synaptic plasticity; especially, when moderate frequency stimulation paradigms are used. 
This points to the physiological importance of the eCB system, largely for learning and 
memory formation. Future work should focus on better understanding the physiological 
implications of these effects on plasticity, as well as better resolving the divergence 
between species. It will also be very important to uncover the possible roles of a novel 
cannabinoid receptor in synaptic modulation. 
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Appendix A: 10 Hz potentiation persists up to 3 hours 
fEPSP amplitude following 10 Hz stimulation shows a sustained potentiation for up to 
180 minutes (n=3) in Sprague Dawley rats. 
 
Appendix A: 10 Hz potentiation persists up to 3 hours.  
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Appendix B: TBS LTP still occurs in WIN55,212-2  
 
Theta burst stimulation (TBS(2)) induces LTP in the presence of WIN55,212-2 in 
Sprague Dawley rats although it is reduced compared to control conditions (128 ± 11.8% 
in WIN55,212-2, n=3,versus 157 ± 7.9% in control, n=16, p<0.05) 
 
Appendix B: TBS LTP still occurs in WN55,212-2 
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Appendix C: SR141716 does not change fEPSP amplitude in C57Blk6 wild type mice 
 
 
Application of 1 !m SR141716 does not change the fEPSP amplitude of responses in 
C57Blk6 wild type mice (105.0 ± 0.05 %, n=8, p=0.37 compared to baseline). 
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Appendix C: SR141716 application does not change fEPSP 
amplitude in C57Blk6 wild type mice. 
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Appendix D : CB1 receptor activation does not inhibit fEPSP amplitude during the 
10Hz stimulation trains. 
 
A) Repetitive stimulation during the two 100 pulse 10 Hz bursts does not cause increased 
potentiation of the fEPSP in CB1(-/-) mice, instead the CB1(-/-) mice are actually less 
potentiated than the wild type mice. 
B) Similar to what is seen in the CB1(-/-) mice, application of SR141716 also does not 
cause increased potentiation of fEPSP during the 10 Hz stimulation protocol, but instead 
SR141716 application depresses the fEPSP compared to control conditions.  
Appendix D: CB1 receptor activation does not inhibit fEPSP 
amplitude during the 10 Hz stimulation trains 
A B 
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Appendix E: Changes in paired pulse ratio in wild type and CB1(-/-) mice following 10 
Hz LTP 
 
The base paired pulse ratio (PPR) in CB1(-/-) mice is less than in wild type mice (1.65 ± 
0.04 in CB1(-/-), n=21 versus 1.75 ± 0.03 , n=33 in wt, p = 0.05). Following 10 Hz 
stimulation PPR is not significantly change in wild type mice (1.71 ± 0.03, n=30, p=0.11) 
but is decreased in CB1(-/-) mice (1.52 ± 0.05, n=21, p<0.01). 
 
Appendix E: Changes in paired pulse ratio in wild type and  
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